440 related articles for article (PubMed ID: 15986370)
41. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Aug; 53(30):683-6. PubMed ID: 15295313
[TBL] [Abstract][Full Text] [Related]
42. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts.
Holmqvist ME; Wedrén S; Jacobsson LT; Klareskog L; Nyberg F; Rantapää-Dahlqvist S; Alfredsson L; Askling J
Arthritis Rheum; 2009 Oct; 60(10):2861-9. PubMed ID: 19790058
[TBL] [Abstract][Full Text] [Related]
43. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Nilsson JA; Petersson IF; Lindqvist E; Saxne T; Geborek P
Ann Rheum Dis; 2007 May; 66(5):670-5. PubMed ID: 17158824
[TBL] [Abstract][Full Text] [Related]
44. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis.
di Comite G; Marinosci A; Di Matteo P; Manfredi A; Rovere-Querini P; Baldissera E; Aiello P; Corti A; Sabbadini MG
Ann N Y Acad Sci; 2006 Jun; 1069():428-37. PubMed ID: 16855170
[TBL] [Abstract][Full Text] [Related]
45. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
Chakravarty EF; Michaud K; Wolfe F
J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
[TBL] [Abstract][Full Text] [Related]
46. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
47. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
La DT; Collins CE; Yang HT; Migone TS; Stohl W
Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
[TBL] [Abstract][Full Text] [Related]
48. [TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports].
Tengstrand B; Ernestam S; Engvall IL; Rydvald Y; Hafström I
Lakartidningen; 2005 Dec 5-11; 102(49):3788-90, 3793. PubMed ID: 16408702
[TBL] [Abstract][Full Text] [Related]
49. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis.
Inanc N; Aydin SZ; Karakurt S; Atagunduz P; Yavuz S; Direskeneli H
J Rheumatol; 2009 Dec; 36(12):2675-81. PubMed ID: 19918035
[TBL] [Abstract][Full Text] [Related]
50. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
Pachot A; Arnaud B; Marrote H; Cazalis MA; Diasparra J; Gouraud A; Mougin B; Miossec P
J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
[TBL] [Abstract][Full Text] [Related]
51. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
Wallis RS
Arthritis Rheum; 2008 Apr; 58(4):947-52. PubMed ID: 18383389
[TBL] [Abstract][Full Text] [Related]
52. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada.
Brassard P; Lowe AM; Bernatsky S; Kezouh A; Suissa S
Arthritis Rheum; 2009 Mar; 61(3):300-4. PubMed ID: 19248128
[TBL] [Abstract][Full Text] [Related]
53. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
[TBL] [Abstract][Full Text] [Related]
54. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data.
Keystone EC
J Rheumatol; 2011 Aug; 38(8):1552-62. PubMed ID: 21572154
[TBL] [Abstract][Full Text] [Related]
55. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Carroll MB; Bond MI
Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
[TBL] [Abstract][Full Text] [Related]
56. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives.
Ekström K; Hjalgrim H; Brandt L; Baecklund E; Klareskog L; Ekbom A; Askling J
Arthritis Rheum; 2003 Apr; 48(4):963-70. PubMed ID: 12687538
[TBL] [Abstract][Full Text] [Related]
57. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
[TBL] [Abstract][Full Text] [Related]
58. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment.
Denis B; Lefort A; Flipo RM; Tubach F; Lemann M; Ravaud P; Salmon D; Mariette X; Lortholary O;
Clin Microbiol Infect; 2008 Feb; 14(2):183-6. PubMed ID: 18076664
[TBL] [Abstract][Full Text] [Related]
59. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
Weisman MH
J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621
[TBL] [Abstract][Full Text] [Related]
60. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
